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Abstract
As solid organ transplantation increases and patient survival improves, it will become 
more common for these patients to present for nontransplant surgery. Recipients may 
present with medical problems unique to the transplant, and important considerations 
are necessary to keep the transplanted organ functioning. A comprehensive preoperative 
examination with specific focus on graft functioning is required. The anesthesiologist 
needs to pay close attention to considerations of immunosuppressive regimens, blood 
product administration, drug interactions as well as the risk and benefits of invasive 
monitoring in these immunosuppressed patients. This article reviews the post-transplant 
physiology and anesthetic considerations for patients after solid organ transplantation.
Keywords: anesthesia methods, intraoperative monitoring, organ transplantation 
physiology, perioperative care, solid organ transplantation
1. Introduction
The number of solid organ transplants performed worldwide is ever increasing. The improved 
survival rates are the result of well-established surgical techniques and effective immunosup-
pressive therapy. All this has led to an increase in number of patients who present for either 
elective or emergency non-transplant surgery [1, 2]. Laparotomy for small bowel obstruc-
tion, hip arthroplasty given the increased risk of fracture and avascular necrosis as a result 
of chronic steroid use causing bone demineralization and osteoporosis, lymph node excision 
and biopsy because of increased risk of lymphoproliferative disease, native nephrectomy in 
kidney transplant recipients, bronchoscopy in lung recipients, biliary tract interventions in 
liver recipients, and abscess drainage because of increased risk of infection are just a few of 
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the increased surgical needs in this population. These patients cannot always return to the 
transplant facility for surgery, so it is incumbent on all anesthesiologists to review periopera-
tive issues associated with transplantation.
Perioperative anesthetic management in majority of recipients is similar to the standard prac-
tice for any patient. However, we must bear in mind some essential considerations: problems 
of allograft denervation, the adverse effects of immunosuppression and its interaction with 
anesthetic drugs, the risk of infection, and the potential for organ rejection. When transplant 
recipients require nontransplant surgery, immune competence can be altered from the stress 
of surgery, acute illness, or disruption of the regimen by inexperienced providers [3].
Preoperative assessment of any transplant recipient undergoing non-cardiac surgery should 
focus on graft function and rejection, risks of infection, and function of other organs, particu-
larly those that may be compromised due to either immunosuppressive therapy or dysfunc-
tion of the transplanted organ itself and drug interactions. There is no ideal anesthetic for use 
in organ transplant recipients. However, certain principles can be applied to all transplant 
patients who undergo anesthesia and surgery [4].
In this chapter, we will give an overview of immunosuppressive therapy and its interaction 
with anesthetic drugs as well as considerations regarding specific transplanted organs (heart, 
lungs, liver, kidney, pancreas, and intestine).
2. Immunosuppression
2.1. Immunosuppression protocol
Transplant patients are always under various regimens of immunosuppressive therapy 
(Table 1). Immunosuppression trends for solid organ transplantation have undergone a 
perceptible shift over the past decade. There are broad therapeutic patterns and numerous 
immunosuppressive protocols depending on transplanted organ, as well as the regional 
differences (country, hospital). However, some strategies are similar. We distinguish 
induction immunosuppressive therapy and maintenance of immunosuppressive therapy. 
Induction of immunosuppression begins immediately before the organ implantation. 
Antibodies are prescribed for the majority of kidney, pancreas, and intestine recipients 
and for just under half of thoracic organ recipients. It is extremely uncommon in liver 
transplantation [5]. Maintenance of immunosuppression involves one of the drugs from 
each group: calcineurin inhibitors (CNI), antimetabolites, and steroids.
The immunosuppressant strategy has been changing over the years. CNIs are still being used 
for the maintenance of immunosuppressive therapy, though shifting from cyclosporine to 
tacrolimus is being observed [6]. Modifications are also made among antimetabolites, from 
azathioprine to mycophenolate mofetil, and it is more common to decrease corticosteroid use 
or even implement steroid-free protocol in suitable transplant recipients [7, 8].
Most of the commonly used immunosuppressants have a narrow therapeutic index and display 
significant variability in blood concentrations between individuals. In transplant recipients, 
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both supratherapeutic and subtherapeutic drug concentrations can have devastating results. 
Subtherapeutic levels increase the risk of transplant rejection, and supratherapeutic levels 
(overimmunosuppression) can lead to infection and/or drug-specific side effects. Importantly, 
the incidence of acute rejection has declined over the past decade. Treatments for acute rejec-
tion continue to include high-dose corticosteroid and antibody therapies [9].
2.2. Side effects and drug interactions
Chronic immunosuppressive therapy has its adverse effects such as lowered seizure thresh-
old, diabetes, hypertension, hyperlipoproteinemia, decreased glomerular filtration, hyperka-
lemia, hypomagnesemia, increased risk of infection and tumors, pancytopenia, osteoporosis, 
and poor wound healing. This may have some impact on perioperative management and 
choice of anesthetic agents (Table 2) [10].
The blood level of both cyclosporine and tacrolimus must be kept within the indicated thera-
peutic range to get the desired effect. The perioperative fluctuation of the plasma level of these 
two drugs should be strictly monitored. There is a significant reduction of drug blood level by 
dilution with volume infusion or cardiopulmonary bypass in cardiac surgery [11]. Both these 
drugs are metabolized by cytochrome P-450 system of liver, and therefore many of the drugs 
administered perioperatively can affect their plasma levels [12, 13]. A better understanding of 
General names Generic names Brand names
Corticosteroids Prednisone
Methylprednisolone
Calcineurin inhibitors Tacrolimus (or FK-506)
Cyclosporine (or cyclosporine A)
Prograf
Sandimmune, Neoral, Gengraf, Eon, 
SangCya, generic cyclosporine
Antimetabolites Azathioprine
Cyclophosphamide
Mycophenolate mofetil
Mycophenolate sodium
Imuran
Cytoxan, Neosar
CellCept
Myfortic
Polyclonal antibodies Antithymocyte globulin (rabbit)
Antithymocyte globulin (equine)
NRATG, NRATS, ALG
Thymoglobulin
ATGAM
Anti-CD3 monoclonal antibodies Muromonab-CD3 Orthoclone OKT3
Anti-CD52 monoclonal 
antibodies
Alemtuzumab Campath
Anti-IL-2 receptor monoclonal 
antibodies
Basiliximab
Daclizumab
Simulect
Zenapax
TOR inhibitors (or rapamycin) Sirolimus Rapamune
Table 1. Most commonly used immunosuppressive drugs.
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pharmacokinetics over the years, allows now days a reduction of immunosuppressant dose 
in elderly patients while maintaining the therapeutic level [14].
In the hospital settings, almost 3–5% of adverse drug reactions are due to drug-drug interac-
tions. It is estimated that the percentage is even higher in solid organ transplant recipients 
dependent on immunosuppressive therapy. Reactions can be among two immunosuppres-
sants or between the immunosuppressant and other drugs [15]. Due to the fact that the admin-
istration of cyclosporine (CyA) and tacrolimus (Tac) is ever increasing, we give an overview of 
their interaction with other drugs (Table 3).
During anesthesia, we provide a range of drugs from different groups, which increase the 
possibility of drug interaction and thus potentially endanger the patient in the perioperative 
period. One should keep in mind that many pharmacokinetic and pharmacodynamic interac-
tions can occur among the drugs that patients take after transplantation, due to cytochrome 
P450 enzyme system induction or inhibition by another drug. There are few data concerning 
interaction between immunosuppressive drugs and anesthetic agents. Most of the evidence is 
based on clinical practice and occasional case reports or case studies. Large randomized con-
trolled trials involving either general or regional anesthesia are still lacking. Table 4 describes 
the effect of various anesthetic agents on immunosuppressant and vice versa.
Data on the effects of general anesthesia on cyclosporine or tacrolimus pharmacokinetics in 
humans are limited. Most of the inhalational anesthetic agents are well tolerated unless there 
is a significant heart failure. However, caution is advised in concurrent administration of oral 
cyclosporine and isoflurane anesthesia. Subtherapeutic blood levels have been reported in 
patients who received peroral drug form less than 4 hours preoperatively. It is probably due 
to a reduction in gastric emptying and absorption from the proximal small bowel, which can 
occur during isoflurane anesthesia [16]. Steady-state blood levels of cyclosporine and cyclo-
sporine clearance are not altered by isoflurane/nitrous oxide anesthesia in animal model [17].
CyA Tac Aza Ster MMF ATG OKT3
Anemia – – + – + – –
Leucopenia – – ++ – + + +
Thrombocytopenia – – – – + – –
Hypertension ++ + – + – – –
Diabetes + ++ – ++ – – –
Neurotoxicity + + – + – – –
Renal insufficiency + ++ – – – – –
Anaphylaxis – – – – – + +
Fever – – – – – + +
ATG = anti-thymocyte globulin; Aza = azathioprine; CyA = cyclosporine A; MMF = mycophenolate mofetil; 
OKT3 = monoclonal antibodies directed against CD-3 antigen on the surface of human T-lymphocytes; Ster = steroids; 
and Tac = tacrolimus.
Table 2. Side effects of immunosuppressive that have direct impact on anesthetic and perioperative management [1].
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Cyclosporine and tacrolimus increase blood level of benzodiazepines. Transplanted patients 
need dose modification [12, 13]. Propofol infusion does not modify the cyclosporine concentra-
tion. It is considered to be a suitable agent for intravenous anesthesia in cyclosporine-treated 
patients, provided a close postoperative monitoring of cyclosporine blood concentrations is 
maintained [18]. Cyclosporine tends to increase the analgesic effect produced by fentanyl, but 
the mechanism is unclear [19].
Most of relaxants can be used safely. Cyclosporine enhances the effects of muscle relax-
ants. Prolonged neuromuscular block in patients receiving cyclosporine after vecuronium 
and pancuronium administration has been described [20, 21]. Atracurium and cisatracurium 
Drug class Drug Effect on blood level
Adverse effect
Benzodiazepines Diazepam, midazolam, alprazolam, 
flurazepam, clonazepam
↑ Benzodiazepines
Antibiotics Erythromycin, metronidazole, 
norfloxacin, levofloxacin
↑ CyA and Tac level
Antimicrobial Rifampicin ↓ CyA and Tac level
Antimalarial Chloroquine, mefloquine ↑ CyA and Tac level
Antifungal Ketoconazole, fluconazole, itraconazole, 
voriconazole, amphotericin B
↑ CyA and Tac level
Renal dysfunction
Anti-retroviral Ritonavir, atazanavir, darunavir, 
cobicistat, delaviridine
↑ CyA and Tac level
Cardiovascular drugs 
(antiarrhythmics and calcium channel 
blocker)
Amiodarone, lidocaine, quinidine, 
verapamil, diltiazem, amlodipine, 
felodipine
↑ CyA and Tac level
QT prolongation by amiodarone 
and quinidine
Statins Simvastatin, atorvastatin, lovastatin, 
pravastatin
↑ Statin concentration
Anticoagulants Apixaban, dabigatran, rivaroxaban ↑ Anticoagulant concentration
Oral hypoglycemics Sulfonylurea, biguanides ↑ CyA level
Gastrointestinal Metoclopramide, omeprazole, 
lansoprazole, octreotide, cimetidine, 
ranitidine
↑ CyA and Tac level
Renal dysfunction
QT prolongation by octreotide 
with Tac
Analgesics Nonsteroidal anti-inflammatory drugs ↑ CyA and Tac level
Renal dysfunction
Antipsychotics Haloperidol, desipramine, fluoxetine, 
trazodone, pimozide
↑ CyA and Tac level
↑ Pimozide level
Hormones Estrogen and testosterone preparation ↑ CyA and Tac level
Others Bosentan, carbamazepine ↓ CyA and Tac level
CyA = cyclosporine A; Tac = tacrolimus.
Table 3. Drugs that interact with cyclosporine A and tacrolimus.
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are preferred agents because their elimination is not affected by renal or hepatic function. 
Therefore, patients receiving cyclosporine as immunosuppressive therapy may require a 
smaller dose of nondepolarizing muscle relaxant and the recovery time may be prolonged 
[22]. Neostigmine can lead to bradycardia and cardiac arrest in patients with heart transplan-
tation despite the concurrent use of an antimuscarinic agent [23]. Bupivacaine and ropiva-
caine can be safely used through regional routes without any side effects [24, 25].
3. Anesthesia and preoperative care
3.1. Preoperative assessment of transplant recipients
Many transplant recipients live relatively normal and productive lives, but often have lim-
ited physical reserves. A successful transplant abolishes the symptoms and replaces function 
of the failed organ, but often there are persistent abnormalities from the underlying or pre-
existing illness that may have caused the organ failure or chronic physiologic abnormalities 
resulting from the organ failure itself. The preoperative evaluation of transplant recipients 
undergoing non-transplant surgery should include graft function, signs of rejection, presence 
of infection, and function of other organs.
Allograft rejection may occur at any time during the post-transplant period, especially when 
discontinuing the use of immunosuppressants. Chronic rejection is the most significant medi-
cal obstacle to long-term morbidity-free allograft survival. The incidence is thought to pro-
gressively increase with time after transplantation, but after a period of 5 years, it affects about 
10% of liver to around 60% of lung allograft recipients [26]. Chronic organ rejection results in a 
progressive deterioration of organ function (assessed trough laboratory tests) and is the main 
cause of late mortality in the transplant recipients. Mortality rate is high if rejection remains 
untreated before surgery [27]. Therefore, the presence of any degree of rejection should be 
ruled out and urgently managed preoperatively with increased immunosuppression.
Anesthetic agent Effect with immunosuppressive drugs
Isoflurane ↓ Clearance of oral CyA
Thiopental Nil
Benzodiazepines ↑ Blood level of benzodiazepines
Propofol Nil
Etomidate Nil
Opioids CyA ↑ analgesic effect produced by fentanyl
Muscle relaxants Prolonged neuromuscular blockade
Neostigmine Caution in heart transplant patients
Local anesthetics Bupivacaine and ropivacaine can be safely used
Table 4. Effect of specific anesthetic agent on immunosuppressive drugs.
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Immunosuppressed patients are at risk of infections that may be bacterial, viral, fungal, or 
protozoan. Infection is a significant cause of morbidity and mortality after transplantation 
[28]. Its presence should also always be preoperatively ruled out (by obtaining laboratory, 
radiologic, and microbiology tests). It is imperative to emphasize that the immunosuppressed 
patient may not present the typical signs and symptoms of infection (i.e. fever, leukocyto-
sis). Microbiology advice should be strongly sought for prevention as well as strict control of 
infection. Any infection should be treated preoperatively [29].
Although transplant patients are considered as risk hosts for infection because of their immune 
status, there is no evidence to suggest different bacteriology of surgical site infections than for 
the general population. Antimicrobial coverage need not be expanded to include atypical or 
opportunistic organisms as long as active infection with such an organism is not present or 
suspected [30]. Prophylaxis with broad spectrum antibiotic should be administered 1 hour 
before surgical incision (depending on hospital protocol) (Table 5).
Transplanted patients may also suffer from diabetes, hypertension, epilepsy, renal dysfunc-
tion, bone marrow suppression, lymphoproliferative disorders, and adrenal insufficiency as 
the side effects of chronic immunosuppressive therapy [31]. Hepatobiliary and pancreatic dis-
eases are relatively common after transplantation, as well as the upper gastrointestinal bleed-
ing secondary to peptic ulcer disease. Surgical stress, corticosteroids, and mycophenolate may 
contribute to gastrointestinal ulcers [32]. So, it is absolutely necessary to provide stress ulcer 
prophylaxis for transplanted patients.
The transplant patient population is considered as high-risk group for developing venous 
thromboembolism (VTE) given the fact that most of these patients have multiple identifi-
able risk factors [33]. However, the exact risk of developing VTEs in these patients is not 
clearly defined in the literature, nor there are clear guidelines regarding the appropriate use 
of thromboprophylaxis in transplant recipients [34]. In our opinion, VTE prophylaxis should 
be tailored to the patient’s specific needs in accordance with current guidelines [35].
Operation Recommended antibiotic prophylaxis
Cardiothoracic surgery Cefazolin, cefuroxime, or cefamandole.
If patient has a β-lactam allergy: vancomycin or clindamycin
Vascular surgery Cefazolin or cefuroxime.
If patient has a β-lactam allergy: vancomycin with or without gentamycin, 
or clindamycin
Colon surgery Oral: neomycin plus erythromycin base, or neomycin plus metronidazole.
Parenteral: cefoxitin or cefotetan, or cefazolin plus metronidazole
Hip or knee arthroplasty Cefazolin or cefuroxime.
If the patient has a β-lactam allergy: vancomycin or clindamycin
Vaginal or abdominal hysterectomy Cefazolin, cefotetan, cefoxitin or cefuroxime
Table 5. Antimicrobial prophylaxis for selected surgical procedures [30].
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3.2. Preoperative assessment and premedication
The transplant team as well as the attending anesthesiologist and surgeon should have a 
good coordination during perioperative period, especially if a major surgical procedure is 
planned. A comprehensive preoperative evaluation by the anesthesiologist should include: 
evaluation of the graft function, presence of infection, function of other organ systems, the 
presence of concomitant diseases as well as the preoperative performance or functional sta-
tus. Adherence to the fundamental principles of preoperative evaluation along with a high 
level of vigilance is required. Information and medical history should be gathered from the 
medical records, interview with the patient and/or next of kin or guardian. If medical infor-
mation is unavailable, attempts should be made to contact the transplant center for pertinent 
history. Other useful information from the transplant center includes their most recent evalu-
ations and recent data on graft function and general health of the patient. Close communica-
tion with the transplant team may be the single most important step in preparing the patient 
for surgery and developing a perioperative anesthetic plan.
A thorough review of systems along with a physical examination is essential in this popula-
tion. Findings such as recent weight gain, edema, dyspnea, sweats, malaise, fever, rashes, 
abdominal pain, abnormal breath sounds on auscultation, and changes in stool or urine out-
put are some of the potential signs and symptoms of infection or rejection.
The following investigations should be available preoperatively.
1. Laboratory parameters:
a. Complete blood count (to rule out bone marrow suppression)
b. Electrolytes
c. Renal function tests
d. Liver function tests
e. Coagulation tests
f. Biomarkers (i.e. brain natriuretic peptide)
2. Chest radiograph
3. Electrocardiogram
4. Echocardiography
5. Miscellaneous: depending on the type of surgery and transplanted organ (i.e. coronary 
angiography, stress test, spirometry, biopsy)
Each preoperative evaluation and testing should be considered individually based on the 
target organ system(s) to be evaluated, the patient’s medical history, and the inherent risks of 
the upcoming surgical procedure.
Cardiovascular disease is a major cause of mortality and morbidity among organ transplant 
recipients, especially in those with chronic kidney disease or previous heart transplant, making 
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the risk of a perioperative cardiovascular event a legitimate concern. Many transplant recipi-
ents have undergone complete cardiac testing and in some cases, interventions, before their 
transplant surgery. Records of the testing and interventions can be easily obtained from the 
transplant center to be used for comparison and consideration before the upcoming surgery. 
We must also bear in mind that many of these patients may have asymptomatic coronary dis-
ease as a result of diabetes or the transplant itself [36].
If unexpected abnormal findings are identified on physical examination or laboratory test-
ing, symptomatic changes outside the patient’s baseline are documented, or suspicion for 
rejection or infection exists during the preoperative evaluation, it should be considered to 
postpone any surgery that is non-urgent or elective. The patient should also be expeditiously 
referred back to the transplant center, cardiologist, or other consulting physician as indicated.
Standard premedication may be used, as in non-transplant patients. However, dose adjustment 
for some drugs is needed (Table 3). Antibiotic, stress ulcer and VTE prophylaxis administra-
tion is recommended (as mentioned above). Supplemental steroids are not necessary for stress 
coverage except in post-transplant recipients in whom steroids are recently withdrawn [37].
Post-transplantation diabetes mellitus is a common metabolic consequence of the agents 
of immunosuppressive therapy agents [38]. It is imperative to institute a glycemic control 
plan before the surgery with closely managing intraoperative and postoperative glucose 
control.
The dose of immunosuppressive drugs should not be altered and should be continued post-
operatively to reduce the risk of rejection. Daily monitoring of the steady-state blood level is 
recommended. Oral cyclosporine should be administered 4–6 h before surgery to maintain 
therapeutic blood levels. The alteration of dose of other immunosuppressive drugs dose is not 
required unless the route of administration needs to be changed from oral to intravenous [39].
3.3. General anesthetic considerations
There is no ideal anesthetic plan that can be used for all transplant recipients undergoing non-
transplant surgery. A variety of anesthetic techniques have been successfully used in patients 
with a transplant history including general (inhalational, balanced, and total intravenous), 
neuraxial, and regional anesthesia.
3.3.1. Monitoring
Generally, invasive monitoring is not mandatory and anesthesia should be performed using 
standard European Society of Anesthesiology’s monitoring guidelines [40]. The decision to 
use invasive hemodynamic monitors, placement of central venous access, pulmonary artery 
catheters, or other procedures such as transesophageal echocardiography should be made 
on a case-by-case basis. It should be guided by consideration of the patient’s comorbidities, 
hemodynamic stability, the expertise of the anesthesiologist in placing the invasive devices, 
and by the type of surgery and anesthesia planned. Aseptic technique is of utmost importance 
to minimize exposure to infectious organisms and bacteremia when attempting any invasive 
procedures in this population [41].
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3.3.2. Airway management
Airway management of transplant patients may pose a concern for several reasons. Many 
patients may have pre-existing diabetes mellitus before transplant or acquire diabetes after 
transplant. Diabetic patients can develop limitations in joint mobility caused by glycosylation 
of the connective tissue within their joints [38]. This population is also at increased risk for 
lymphoproliferative disorders secondary to immunosuppressant drugs, and lymphopro-
liferative growth may compromise any part of the airway or mediastinum and cause life-
threatening airway obstruction during sedation and anesthesia [41]. Gingival hyperplasia is 
present at times in patients taking cyclosporine and it may lead to bleeding during airway 
manipulation. Aspiration risk may be increased in transplanted patients as a result of delayed 
gastric emptying and gastropathy [32]. These potential problems should all be taken into con-
sideration when constructing the anesthetic plan for airway management.
Oral endotracheal intubation is preferred over nasal intubation because of the potential of 
infection caused by nasal flora [42]. The use of a laryngeal mask is acceptable (within its 
indications) [43]. Keep in mind that laryngoscopy and tracheal intubation may not produce 
a sympathetic response secondary to the loss of cardiac baroreceptor reflexes in heart trans-
planted patients [44]. Avoid hyperventilation in patients taking cyclosporine and tacroli-
mus because of a decrease in seizure threshold with these two drugs. Early postoperative 
extubation is preferred if possible to prevent the development of nosocomial or ventilator-
associated pneumonia [45].
3.3.3. General anesthesia
All inhalational and intravenous anesthetics have been used with success in transplant recipi-
ents. The choice of anesthetics and adjunctive drugs should be determined by the type of 
surgery and condition of the patient. As a general guideline, if hepatic and renal functions 
are normal, all standard anesthetic medications and adjuncts may be used. Some special con-
siderations for each type of organ transplant are discussed in the section on organ-specific 
considerations.
3.3.3.1. Intravenous anesthetics
The selection and administration of intravenous anesthetics should be guided by the patient’s 
hemodynamic status, the drug’s cardiovascular effects, and pharmacokinetic properties. 
Premedication with benzodiazepines is acceptable. Caution should be used in patients with 
hepatic or renal insufficiency as effects may be prolonged. Also, the dose of barbiturates 
should be adjusted in patients with hepatic insufficiency to avoid prolonged effects.
Propofol is extensively metabolized by the liver to inactive glucuronic acid metabolites that 
are excreted by the kidneys. Nevertheless, there seems to be no need for dose adjustments in 
patients with hepatic or renal failure indicating an extrahepatic route of elimination as well [46]. 
Caution should be used in patients with cardiovascular compromise as propofol can worsen 
cardiac contractility, compromise cardiac preload, cause bradycardia, and lower systemic vas-
cular resistance culminating in diminished cardiac output and mean arterial pressure.
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Etomidate does not have the cardiac depressant effect of barbiturates and propofol. 
Etomidate is metabolized rapidly by hydrolysis within the liver and by plasma esterases and 
also does not require dosage adjustment in renal or hepatic disease. One unique characteris-
tic of etomidate is its ability to inhibit enzyme necessary for the synthesis of cortisol [47]. This 
may have clinical significance in patients who already have adrenal suppression as a result 
of exogenous corticosteroid use.
Ketamine is metabolized via the hepatic cytochrome P-450 system. Therefore, the clinical 
effects of ketamine are prolonged in the presence of hepatic insufficiency. The usual cardiac 
stimulating effects caused by central stimulation of the sympathetic system are not present 
in the denervated heart, but ketamine can still increase systemic vascular tone. Ketamine has 
neuroexcitatory effects and is known to cause myoclonic activity. It would be wisely to pro-
ceed with caution if the katamine is administered in patients who simultaneously take cyclo-
sporin due to its potential for neurotoxicity.
3.3.3.2. Inhalational anesthetics
All inhaled anesthetics have been used in transplanted patients with success. Although halo-
thane is nowadays rarely used, nevertheless it is necessary to mention its potential for hepa-
totoxicity and direct cardiac depressant effects. Most commonly used volatile anesthetics are 
isoflurane, sevoflurane, and desflurane. There does not seem to be a significant clinical advan-
tage or disadvantage of one over the others. The choice of inhaled anesthetic can be dictated 
by the anesthesiologist’s preference, experiences, and comfort with the anesthetic [48]. It is 
probably prudent to avoid prolonged use of N2O because of the potential risk of bone mar-
row suppression and the potential for altered immunologic response [49].
3.3.3.3. Opioids
Fentanyl is suitable and safe for short-term use during surgery. However, if used for long 
duration, the pharmacodynamic effects should be monitored due to accumulation effect. 
Reduced renal and liver function does not significantly alter the clearance and half-life of 
sufentanil. Tissue and blood esterases mainly metabolize remifentanil and its metabolite, 
excreted via kidneys, has low potency [50].
Among opioids used for postoperative pain treatment (morphine, codeine, oxycodone, and 
tramadol) have to be used with caution. Some of their active metabolites accumulate in renal 
failure and can mediate CNS and respiratory depression. Transdermal buprenorphine and 
methadone appear to be safe to use even in patients with renal dysfunction [51].
3.3.3.4. Neuromuscular blockade
The decision to use neuromuscular blockade should be based on the type of surgery and 
actual need for muscle relaxation during the procedure or the need to optimize intubating 
conditions. The choice of specific neuromuscular blocking agent should be dictated by length 
of surgery, underlying medical illnesses (i.e. myasthenia or other neuromuscular disorders), 
history of malignant hyperthermia, and the functional state of the patient’s kidney and liver.
Anesthetic Considerations in Transplant Recipients for Nontransplant Surgery
http://dx.doi.org/10.5772/intechopen.74329
239
In the group of non-depolarizing drugs, it is preferable to use short-acting relaxants (mivacu-
rium) or intermediate-acting agents independent of kidney and liver function (cisatracurium, 
atracurium). Vecuronium, rocuronium, and pancuronium can have prolonged effects in the face 
of hepatic or renal insufficiency. They require dose adjustments, close neuromuscular monitor-
ing, and evidence of full reversal before extubation [52]. Some immunosuppressive drugs (i.e. 
azathioprine and cyclosporine) can prolong the action of the neuromuscular blocking agents [22].
Succinylcholine, the only depolarizing agent available, can be used in organ transplant recipi-
ents in the need for rapid sequence intubation and rapid airway control. It should be avoided 
only if there are other clinical reasons, such as hyperkalemia, muscular dystrophy, or history 
of malignant hyperthermia [53].
3.3.3.5. Anticholinesterase drugs
Most of the cholinesterase inhibitor drugs are eliminated through the kidneys (neostigmine, 
edrophonium, and pyridostigmine). Caution is advised in renal failure. Several reports 
described that neostigmine may produce a dose-dependent life-threatening bradycardia in 
heart transplant recipients, whereas another publication described the safe use of neostigmine 
[54]. Reversal of neuromuscular block with sugammadex is another possibility, but limited 
data exist in literature [55].
3.3.4. Regional and neuraxial anesthesia
The decision to perform a regional or neuraxial anesthetic technique in a previously trans-
planted patient must be made on an individual basis. We must carefully consider potential 
benefit and risks of these techniques as well as the anesthetic alternatives when constructing 
the anesthetic plan in this population. There may be several advantages to choosing a neuraxial 
or regional technique in this population. Superior analgesia over systemic opioids, especially 
in patients who may have narcotics tolerance as a result of long-term opioid use, reduced pul-
monary complications, and decreased incidence of graft occlusion are just a few of the benefits 
of regional and neuraxial anesthesia [56]. Clinically relevant doses of bupivacaine and ropiva-
caine, which are commonly used local anesthetics for neuraxial anesthesia, do not seem to result 
in toxic levels or increased risk of toxic effects in renal and liver transplant recipients. However, 
it is important to be prepared for the risk of hypotension because of pre-existing autonomic neu-
ropathy and cardiac denervation in this population. Cautious correction of hypovolemia before 
epidural or spinal anesthesia may help to attenuate the hypotension. Concurrent hemodynamic 
monitoring is imperative during the procedure. Direct and indirect-acting adrenergic agonists 
should be readily available along with emergency airway supplies.
The consideration of spinal or epidural anesthesia is appropriate in this population as long as 
there is no increased risk for bleeding complications. It is necessary to perform a total blood 
count to exclude bone marrow suppression, especially thrombocytopenia, and coagulation tests 
(PT, INR, APTT, and fibrinogen). Peripheral nerve blocks became popular anesthetic option due 
to hemodynamic stability and better postoperative analgesia. Some studies show no difference 
in duration of peripheral nerve blocks in patients after transplantation compared to the general 
surgical population [57, 58]. Nevertheless, large prospective randomized trials are still lacking.
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Although the risk of infectious complications is very low, it is important to be highly vigilant 
when monitoring these patients after a neuraxial anesthesia as the attenuated inflammatory 
response may diminish the typical signs and symptoms of infection [59]. Again, aseptic tech-
nique and a mask should be considered essential when performing these procedures.
3.3.5. Postoperative care management
Regardless of the procedure performed, successful outcomes also depend on optimal post-
operative care. Depending on the type of surgery, patients’ comorbidities, and preoperative 
condition, patient is after surgery transferred either to intensive care unit (ICU) or post-
anesthesia care unit (PACU). Adequate monitoring is tailored accordingly [60]. We reduce 
the delirium incidence by minimizing sedation, speed up extubation, and facilitate early 
ambulation and physical rehabilitation. Appropriate analgesia is essential component of 
postoperative surgical care. Opioids are the mainstay of analgesia in the early postoperative 
phase after major surgery. Parenteral paracetamol is an effective analgesic agent and may 
spare narcotics. There is no evidence of an increased risk of hepatotoxicity [61]. Once extu-
bated, patient-controlled analgesia (PCA) devices are effective and well received by patients 
and nurses. Non-steroidal anti-inflammatory drugs should be avoided because of the risk 
of adverse interactions (e.g., gastrointestinal hemorrhage, nephrotoxicity, hepatic dysfunc-
tion). They augment nephrotoxicity of cyclosporine, as both drugs affect the renal microcir-
culation [62, 63].
Immunosuppressive therapy should be continued during the perioperative period and daily 
monitoring of steady-state cyclosporine or tacrolimus blood levels is recommended [64]. 
The dose of other immunosuppressive drugs should not be altered perioperatively unless 
the route of administration needs to be changed from oral to intravenous. In addition to the 
routine care as those for non-transplant recipients, increased attention should be paid to the 
preload status, renal function, and prevention of infection.
4. Specific anesthetic considerations
4.1. Heart transplant recipients
Transplanted heart is completely denervated, meaning it lacks neural regulating mechanisms 
[65]. Even though, it has the ability to adjust with compensatory mechanisms to the increased 
demands in stress returning the recipients to an active life. Transplanted heart has no sensory 
sympathetic and parasympathetic innervation. Therefore, it has a higher resting heart rate of 
90–110 bpm secondary to the loss of vagal tone. The resting ECG is commonly altered showing 
two P waves: one is from the recipients’ own SA node and the other is the donors’ SA node. 
Patients are at higher risk of developing atrial flutter or atrial fibrillation. The transplanted heart 
is “preload dependent.” Cardiac output becomes dependent on venous return. Therefore, it is 
important to maintain a sufficient systolic pressure and prevent hypovolemia [66].
Although the cardiac index of the transplanted heart is lower than that of normally innervated 
control hearts, it remains in the normal range. The catecholamine response is different from 
Anesthetic Considerations in Transplant Recipients for Nontransplant Surgery
http://dx.doi.org/10.5772/intechopen.74329
241
Drugs SA node 
rate
AV 
conduction
SVR BP CO Remark
Atropine 0 0 0 0 0 Cannot be used in bradycardia
Dopamine ↑ ↑ 0 E ↑
Dobutamine ↑ ↑ 0 ↑ ↑ Effect on HR is more than normal 
heart
Adrenaline ↑ ↑ 0 ↑ ↑
Noradrenaline ↑ ↑ 0 ↑ E
Isoprenaline ↑ ↑ 0 ↓ ↑
Phenylephrine 0 0 0 ↑ E
Digoxin 0 ↓
Milrinone 0 0 ↓ ↑ ↑
Levosimendan 0 0 ↓ ↑ ↑
SA – sinoatrial; V – atrioventricular; SVR – systemic vascular resistance; BP – blood pressure; CO – cardiac output; HR 
– heart rate; 0 – no effect; and E – equivocal.
Table 6. Response of denervated heart to various cardiovascular drugs.
that of normal heart because intact sympathetic nerves are required for the normal uptake 
and metabolism of catecholamines. The receptor density, however, remains unchanged, and 
the transplanted heart can respond to direct-acting drugs (adrenaline and noradrenaline) [67]. 
Isoprenaline and dobutamine have similar effects in both transplanted and normal heart. 
Because atropine has no effect on a transplanted heart, isoprenaline and adrenaline should be 
readily available to manage bradycardia and hypotensive emergencies. In recent years, milri-
none and levosimendan, inotropic vasodilators, have been included in the pharmacological 
arsenal. These drugs increase myocardial contractility without myocardial oxygen consump-
tion (unlike catecholamines). In addition, they lead to arterial and venous vasodilatation and 
afterload decrease [68, 69]. Table 6 summarizes the hemodynamic response of some commonly 
used drugs for resuscitation.
Heart transplant recipients may present with ongoing rejection with myocardial dysfunction, 
accelerated coronary atherosclerosis, or severe dysrhythmias, all of which must be diagnosed 
before surgery. Chronic allograft rejection usually presents as accelerated coronary artery dis-
ease. Therefore, heart transplant recipients may have significant myocardial ischemia without 
any clinical symptoms of pain and silent myocardial infarction on the ECG. Severe rejection 
can lead to significant systolic and diastolic dysfunction [70, 71].
General anesthesia is usually preferred, as there is a possibility of impaired response to hypo-
tension after spinal or epidural anesthesia. A goal of anesthesia in this setting is the avoidance 
of significant vasodilation and acute decrease of the preload. Invasive hemodynamic monitor-
ing is extremely useful during surgery that involves large volume shifts, due to the fact that 
these patients are preload-dependent and may be prone to myocardial dysfunction and/or 
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ischemia. Instead of invasive monitoring, intraoperative transesophageal echocardiography 
may be considered [72, 73]. All preoperative drug therapy should be continued during the 
perioperative period. If a pacemaker is in place, its proper function should be confirmed.
4.2. Lung transplant recipients
Denervation of the lungs after transplantation is associated with a lack of cough reflex below the 
tracheal anastomosis level and are unable to clear secretions unless they are awake. Therefore, 
they are prone to retention of secretions and silent aspiration [74]. These conditions may lead 
potential hazardous conditions especially in general anesthesia, such as bronchoconstriction 
and the increased risk of chest infection. In light of potential complications, it is preferable to 
perform a regional anesthesia whenever possible and if there is no contraindication [75].
Before elective surgery patients should undergo chest radiograph and spirometry to exclude 
chronic rejection and infection [76]. If allograft rejection or infection is suspected, elective sur-
gery should be postponed and appropriate investigations should be performed.
Altered lymphatic drainage in the transplanted lung may cause interstitial fluid accumulation. 
It has been recommended that these patients be treated with diuretics and limited crystalloid 
infusion [77, 78]. Invasive hemodynamic monitoring is often required in heart-lung transplant 
recipients since there is a narrow line between the pulmonary edema occurrence and maintain-
ing cardiac output with fluid load [79].
4.3. Kidney transplant recipients
Kidney transplant recipient have high incidence of cardiovascular diseases, especially elderly 
patients with diabetes and after years of dialysis procedures. Spectrum of disease can range 
from hypertension to severe coronary disease. It is wisely to approach them with caution. 
Cardiovascular complications are the leading cause of death in renal transplant recipients, 
accounting for 32% of all deaths [80].
After successful transplantation, renal function is restored, with no need for renal replace-
ment therapy. Still, beware of prolonged drug action and excretion in kidney transplant 
recipients, due to the fact that their glomerular filtration rate and effective plasma flow can be 
significantly lower than in healthy subjects [81].
You should suspect at chronic graft rejection when azotemia, proteinuria, and hypertension 
are seen [82, 83]. One of the important parameters to consider in the prevention of graft fail-
ure is the maintenance of appropriate renal perfusion pressure. Perioperative fluid manage-
ment must ensure restoration and maintenance of intravascular volume, in order to obtain 
good graft function. Diuretics should not be given without careful evaluation of the patient’s 
volume status.
In anesthetic management, it is prudent to choose drugs that do not rely on the kidney for 
excretion. Nephrotoxic drugs should be avoided [84]. Cardiovascular instability can be pres-
ent after a recipient has been recently hemodialysed due to hypovolemia and hypokalemia, 
causing arrhythmias and increased susceptibility to muscle relaxants [85].
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4.4. Liver transplant recipients
Liver synthetic tests should normalize over time pointing out a good liver graft function. There 
is also gradual decrease of all liver enzyme levels, as graft function becomes normal. Recovery 
of drug metabolism capacity occurs immediately after reperfusion of the liver graft. Liver trans-
plantation itself results in reversal of the hyperdynamic state that characterizes patients with 
end-stage liver disease and cardiac performance improves in the months after transplantation. 
Hypoxemia caused by ventilation/perfusion mismatch is reversed over the course of the first 
postoperative months. Patients with pre-existing true shunts may require more time to achieve 
reversal of hypoxemia, or hypoxemia may not resolve at all [86]. Hepatorenal syndrome gradu-
ally diminishes, renal function improves over time, and creatinine level may become normal. 
However, kidneys are still in danger of injury due to immunosuppression side effects [87].
The most severe complication of liver transplantation is hepatic artery thrombosis. It has 
often been associated with massive transfusion of blood products leading to hemoconcentra-
tion. Therefore, liver transplant recipients should have minimal blood viscosity (hematocrit 
approximately 28%) during the perioperative period [88].
No individual general anesthetic agents are contraindicated when hepatic and renal function is 
normal. If an epidural or spinal anesthesia is planned, clotting studies and platelet counts should 
be normal. Neither regional nor general anesthetic techniques were associated with deterioration 
of liver function assuming proper anesthetic and intensive care management [3, 25].
4.5. Pancreas transplant recipients
Pancreas transplantation provides the most effective method of glycemic and metabolic con-
trol. It can be done as a single organ transplant or simultaneously with kidney (predominantly 
in type 1 diabetes) (SPKT). SPKT is a treatment of choice for uremic diabetic patients when a 
living-related kidney donor is unavailable. After successful transplantation, pancreas trans-
plant recipients do not require insulin to compensate for the stress response to surgery [89].
However, due to long-lasting diabetes effect, these patients are in high risk of developing 
cardiovascular diseases. It is prudent to manage these patients with the assumption that they 
have coronary artery disease [90]. Pancreas recipients still have persistent complications of 
diabetes such as gastropathy and neuropathy. Aspiration risk may be increased as a result 
of delayed gastric emptying. This population is also at increased risk for lymphoprolifera-
tive disorders secondary to immunosuppressant drugs and lymphoproliferative growth 
may compromise any part of the airway or mediastinum and cause life-threatening airway 
obstruction during sedation and anesthesia [91].
Amylase levels in serum and urine should be closely monitored. They can be our only win-
dow in the graft rejection recognition [92]. Glucose levels should also be monitored peri-
operatively. In normal functioning grafts, the suppression of endogenous insulin secretion 
during hypoglycemia is sufficient to enable a normal glucagon response from the trans-
planted pancreas, even in surgical stress [93]. In patients with failed pancreatic grafts, peri-
operative management of glucose levels and acid-base status is the same as that for any 
diabetic patient.
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4.6. Intestine transplant recipients
There are three types of intestine transplantation: isolated intestinal transplantation, trans-
plantation of combined intestine, and liver graft or multivisceral transplantation. The biggest 
problem in intestinal transplantation is graft rejection, and it is the main reason for morbid-
ity and mortality. The diagnosis of rejection is confirmed by clinical symptoms, endoscopic 
appearance, and pathological specimens taken by endoscopy [94].
Denervation and lymphatic dysfunction of the intestine affect intestinal permeability and 
absorption. If the intestinal mucosa barrier is damaged by ischemia, rejection, or enteritis, 
bacteria translocate into the bloodstream and infections are often observed [95]. Some of 
these patients develop diarrhea and lose weight in the early post-transplantation period. Any 
imbalance in the electrolyte and acid-base status should be timely corrected. Fluid adminis-
tration should be closely monitored to assure sufficient splanchnic perfusion. Venous access is 
of major consideration for the anesthesiologist due to chronic use of total parenteral nutrition 
and its thrombotic complications [96].
5. Special cases
5.1. Trauma
It is generally assumed that immunosuppressed patients are more susceptible to the effects 
of soft tissue damage and poor bone healing. Bone loss associated with chronic immunosup-
pressive therapy is a serious problem for most transplant recipients. These patients are prone 
to fractures (i.e. hip or compressive vertebral fracture) [97].
Only a few studies of traumatized transplant recipients have been reported. This is likely 
because of the infrequent presentation of these patients to trauma centers. The most common 
causes of trauma are car accidents and falls. The latest study by Scalea et al. determined that 
outcomes for traumatic injury in patients with organ transplants are not worse than that for 
non-transplant patients, despite common presumptions among physicians [98]. Transplant 
recipients sustaining trauma should receive the same initial resuscitation as any trauma vic-
tim. Patients should be assessed by a transplant surgeon as soon as possible and graft function 
should be closely assessed by a transplant team during hospitalization and after discharge 
from the trauma center [3]. Acute organ rejection within 6 months of admission for trauma is 
reported among 17% of solid organ recipients [99].
Transplant recipients, whose immune systems are already suppressed to prevent organ rejec-
tion, are presumed to be at greater risk of infection from traumatic injury. However, this was 
not observed in two latest studies [100]. Therefore, similar protocols of antimicrobial therapy 
should apply to both transplanted and non-transplanted patients to avoid the overuse of anti-
microbial agents and ensure maintenance of the susceptibility patterns of pathogens.
Studies also show that transplanted organs are rarely injured in traumatic events. This is most 
likely related to careful selection of transplant recipients who are committed to self-care and 
continue to pursue healthy life style after transplantation.
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5.2. Pregnancy
With the advances in transplantation medicine, female organ transplant recipients are able to 
conceive and carry pregnancies successfully to term. This state presents a unique challenge 
to attending physician, obstetrician, and anesthesiologist. These women are at an increased 
risk of comorbidities and obstetric complications. Therefore, all post-transplant pregnancies 
should be considered as high risk, and close monitoring is mandatory. Anesthesiologists 
are involved in the care of these patients for both labor analgesia and operative procedure. 
Anesthetic considerations include the effects of the physiologic changes of pregnancy on the 
transplanted organ, graft function in the peripartum period, and the maternal side effects and 
drug interactions of immunosuppressive agents. Anesthetic management should consider the 
important task of protecting graft function [101, 102].
Data are lacking regarding the optimal transplant-conception interval. The 2005 American 
Society of Transplantation Consensus Conference suggested that pregnancy 1 year after 
transplant is safe as long as the patient has stable graft function. This means: no episodes of 
rejection in the past year, a low risk for opportunistic infections, stable renal function (includ-
ing in those receiving organs other than a kidney), and a low stable dose of maintenance 
immunosuppression [103].
Pregnancy does not appear to cause excessive or irreversible problems with graft dysfunc-
tion if the function of the transplanted organ was stable prior to pregnancy [104]. Maternal 
side effects of immunosuppression therapy include nephrotoxicity, hepatotoxicity, diabe-
tes, and arterial hypertension, which could lead to possible dangerous complications. In 
kidney, heart, or heart-lung transplant recipients, the rate of complications, such as pre-
eclampsia, premature labor, and risk of acute allograft rejection postpartum, is higher than 
that in the non-transplant population [105].
Current immunosuppressant drugs are not thought to be teratogenic and their use cannot 
be discontinued during pregnancy. All immunosuppressants cross the placenta. They are 
not strongly associated with the increased risk of congenital anomalies in the first trimester. 
However, they affect the immune system of fetus during the second and third trimesters and 
may result in premature delivery and low birth weight in newborn [106].
The anesthetic technique for cesarean section depends on indication, functional status of trans-
planted organ, and cardiovascular and hematological status. Central neuraxial blocks are not 
contraindicated if coagulation status is normal. However, documentation of paresthesia is 
important if regional anesthesia is planned. In the case of general anesthesia, all intravenous 
anesthetics and inhalational agents are safe. Neuromuscular function should be monitored 
particularly if the patient is receiving magnesium. Postoperative pain relief is provided with 
narcotics by epidural or spinal route if regional anesthesia is used or by parenteral opioids. 
Non-steroidal anti-inflammatory drugs should be avoided. Thromboprophylaxis should be 
administered because of the high risk of thromboembolic complications in these patients, 
especially after cesarean delivery. The threshold for admission to an intensive care or high-
dependency unit should be low [107].
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5.3. Laparoscopic surgery
Laparoscopic surgery is currently a widely accepted approach to several surgical fields 
because of its advantages in terms of postoperative pain reduction and easy patient recovery. 
The number of minimally invasive surgical procedures performed in transplant recipients is 
constantly increasing [108].
Lymphoceles can be successfully treated surgically after kidney transplantation by laparos-
copy under general anesthesia [109, 110]. There are also reports of successful laparoscopic 
bariatric surgery after simultaneous pancreas and kidney transplantation [111]. Laparoscopic 
cholecystectomy is considered to be safe procedure in the transplant population. It has advan-
tage of short hospital stay, low morbidity, maintenance of oral immunosuppression, and early 
return to preoperative routines. There is however a slightly higher rate of conversion to an open 
cholecystectomy among transplant patients compared to general population (27% vs. 11%, 
respectively) [112, 113]. Generally, laparoscopic approach may be useful even in solid-organ 
transplantation surgery as a diagnostic or treatment procedure in some surgical complications.
5.4. Outpatient and esthetic surgery
With shorter medical procedure duration and fewer complications, there is growth in popu-
larity of outpatient or ambulatory surgery. Procedures performed are broad in scope: knee, 
shoulder, spine and eye surgery (cataract, laser surgery), plastic surgery, some types of 
esthetic surgery, and upper gastrointestinal endoscopy and colonoscopy [114].
Improved immunosuppression and lifespans have afforded solid organ transplant recipients 
the opportunity to seek outpatient and esthetic surgery. Most commonly performed proce-
dures are soft tissue excisions with local flap coverage, facelifts, breast augmentation, and 
abdominoplasty. Among solid organ transplant recipients, kidney transplant recipients most 
often underwent plastic surgery, accounting for over 68% [115]. The complication rate is very 
low and ranges from 4 to 8% [116]. Delayed wound healing or wound disruption is reported 
as the most common complication and is associated with immunosuppression therapy, such 
as steroids [117].
It is extraordinarily important to manage these patients with a multidisciplinary approach. 
They should obtain clearance from the transplant surgeon and from the organ-specific special-
ist. The anesthesiologist should be familiar with the organ-specific needs in the perioperative 
period (i.e. maintaining preload for heart transplant patients, judicious fluid management in 
the renal patient, and avoidance of volatile anesthetics in liver transplants) to avert unintended 
consequences. It is more reasonable to use of general anesthesia over regional in the heart 
transplant patients. Perioperative antibiotic prophylaxis and stress-dose steroids should be 
administered prior to surgery. NSAIDs should be avoided in postoperative pain regimen [118].
Elective esthetic surgery can be performed safely in patients with a history of solid organ trans-
plantation after a careful patient selection and multidisciplinary approach. These patients can 
potentially experience significant improvements in their quality of life with low morbidity.
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6. Conclusion
The increasing prevalence of previously transplanted patients makes it likely that every anesthe-
siologist will care for patients with end-organ failure or a transplanted organ, either for acciden-
tal or transplant-related surgery in the future. Local, regional, or general anesthesia can be safely 
delivered to transplant recipients and a successful anesthetic and perioperative management 
can be provided. However, for the safe management of solid organ recipients, it is essential to 
have an appropriate knowledge of the physiology of the transplanted organ, the pharmacology 
of the immunosuppressive drugs, and the presence of associated organ dysfunction.
Many of the perioperative problems in the transplant population have not been specifically 
studied, and there are no formal recommendations for their management. Additional research 
should be performed in order to identify perioperative issues and facilitate the formulation of 
guidelines for anesthesia in this particular transplanted population.
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